Petersen W, Heilmann C, Garne S
Acta Paediatr Scand. 1987 Jan;76(1):66-9. doi: 10.1111/j.1651-2227.1987.tb10416.x.
In order to compare the efficacy of pancreatic enzyme supplementation as pH-sensitive enteric-coated microspheres Pancrease to that of conventional supplementation with enteric-coated Pancreatin in cystic fibrosis, a double blind cross-over study was conducted. Eleven patients under 12 years of age received each of the enzyme preparations for four weeks. Treatment efficacy was evaluated by means of a symptom score card recording stool frequency, consistency, colour, odour, abdominal cramps and appetite as well as a 3 days fat absorption test. Weight increments were recorded 3 months before the study when patients were on Pancreatin, and 3 months after the study when patients were on Pancrease. In eight of the patients fat absorption was improved on Pancrease, but the difference did not reach statistical significance. However, the patients experienced significantly less dyspeptic symptoms, decreased stool frequency, better appetite and increments in weight were significantly higher on Pancrease compared to Pancreatin.
为了比较pH敏感型肠溶微球胰酶制剂(Pancrease)与传统肠溶胰酶制剂在囊性纤维化患者中的补充效果,开展了一项双盲交叉研究。11名12岁以下患者每种酶制剂各服用4周。通过症状评分卡记录大便频率、性状、颜色、气味、腹部绞痛和食欲,并进行3天脂肪吸收试验来评估治疗效果。在研究前3个月患者服用胰酶时记录体重增加情况,在研究后3个月患者服用Pancrease时记录体重增加情况。8名患者服用Pancrease后脂肪吸收得到改善,但差异未达到统计学意义。然而,与服用胰酶相比,患者服用Pancrease后消化不良症状显著减轻,大便频率降低,食欲改善,体重增加显著更高。